1. Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus.
- Author
-
Barile-Fabris, Leonor A, Fragoso-Loyo, Hilda, Wojdyla, Daniel, Quintana, Rosana, Pons-Estel, Guillermo J, Catoggio, Luis J, García, Mercedes A, Saurit, Verónica, Drenkard, Cristina, Bonfa, Eloisa, Borba, Eduardo F, Sato, Emilia, Tavares Brenol, Joao C, Cavalcanti, Fernando, Da Silva, Nilzio A, Lavras Costallat, Lilian T, Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, and Cardiel, Mario H
- Subjects
LATIN Americans ,SYSTEMIC lupus erythematosus ,HEMOLYTIC anemia ,PROGNOSIS ,DISEASE duration ,DISEASE progression - Abstract
Introduction: Factors related to presentation of neuropsychiatric (NP) SLE manifestations, early in the course of the disease, and during follow up have not been clearly established. Purpose: To identify disease and non-disease related factors associated with NP manifestations in early SLE. Methods: We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We evaluated the association of demographic, clinical and laboratory data with NP involvement during follow-up. Statistical methods: Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Results: Factors independently associated with NP manifestations were: mestizo ethnicity (HR 1.701, 95% CI 1.282–2.258, p = 0.0002), myalgias/myositis (HR 1.832, 95% CI 1.335–2.515, p = 0.0002), pneumonitis (HR 2.476, 95% CI 1.085–5.648, p = 0.0312), shrinking lung (HR 2.428, 95% CI 1.074–5.493, p = 0.0331) and hemolytic anemia (HR 1.629, 95% CI 1.130–2.347, p = 0.0089). Longer disease duration at cohort entry (13 to 24 months) was associated with a lower risk of developing NP manifestations (HR 0.642, 95% CI 0.441–0.934, p = 0.0206). Conclusions: Patients with myalgias/myositis, pneumonitis, shrinking lung and hemolytic anemia are at higher risk of NP involvement, whereas longer disease duration at cohort entry is associated with a lower risk of developing NP involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF